繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Skye Bioscience Starts Screening Patients for Phase 2 Trial of Potential Weight Loss Drug

2024-08-22 19:31

07:31 AM EDT, 08/22/2024 (MT Newswires) -- Skye Bioscience (SKYE) said Thursday that it has started screening patients for a phase 2 clinical trial of nimacimab as a weight loss therapeutic for patients with obesity.

The company said the trial is targeting enrollment of 120 patients, with weight loss as the primary endpoint. Secondary endpoints include safety, tolerability, and neuropsychiatric and cognitive evaluation, among others, Skye Bioscience added.

Interim data from the trial is expected in Q2 2025 and final data in Q4 2025, the company said.

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。